Turing - Ron Tilles
And finally, we couldn’t start the year without some good news:
‘Pharma Bro’ Martin Shkreli (pictured) who made headlines last year when he raised the price of off-patent HIV drug Daraprim from $13.50 to $750 per pill / bought an exclusive Wu-Tang Clan album for $2m, resigned from his role at Turing Pharmaceuticals just before Christmas, and Chairman of the Board Ron Tilles has taken over as interim CEO.
In a statement a day after Shkreli was arrested on fraud charges, Tilles thanked him for helping “build Turing Pharmaceuticals into the dynamic research focused company it is today,” and wished him the best in his future endeavours.
Turing posted a separate statement saying that Shkreli’s legal matters “are personal and have no bearing on Turing Pharmaceuticals.”